ArticleNPJ digital medicine2026
Noninvasive evaluation and clinical value prediction of tumor-infiltrating neutrophil-to-T-cell ratio in pancreatic ductal adenocarcinoma.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06760234 (Prediction of Pancreatic Cancer Prognosis Using a Multimodal Deep Learning Model Based on Intratumoral Immune Microenvironment), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prediction of Pancreatic Cancer Prognosis Using a Multimodal Deep Learning Model Based on Intratumoral Immune Microenvironment
Who cites it
2 citing papers in PubMed.
- Biofabrication and artificial intelligence strategies for investigating solid- and fluid-pressure mechanobiology in pancreatic ductal adenocarcinoma.Cancer metastasis reviews · 2026Review
- Identification of a novel PANoptosis-associated prognostic signature and immune landscape analysis in neuroblastoma with experimental validation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
In pancreatic ductal adenocarcinoma (PDAC), the tumor immune microenvironment (TIME) is central to prognosis and therapeutic response, yet predictive biomarkers are still lacking. Here, we used PDAC patients from TCGA, CPTAC, and multiple centers to investigate and validate the relationship between the prognosis and tumor-infiltrating neutrophil-to-T-cell ratio (NTR) in the TIME, including the correlation of NTR with chemotherapy response in PDAC. We developed seven artificial intelligence models to evaluate NTR in the TIME, then evaluated their performance. The multi-modal ROI-model, designated PORCELAIN (Pancreatic Cancer Tumor-Infiltrating Neutrophil-to-T-Cell Ratio Evaluation with Artificial Intelligence), achieved superior external validation performance, demonstrating significant stratification of overall survival and recurrence-free survival. The NTR in the TIME is a potential biomarker for PDAC prognosis and treatment stratification. Importantly, PORCELAIN provides a noninvasive approach to assess NTR in the TIME, offering potential value for clinical management. Trial registration number: NCT06760234.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.